HomeCompareHLOSF vs GBDC

HLOSF vs GBDC: Dividend Comparison 2026

HLOSF yields 90.91% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $18.11M in total portfolio value· pulled ahead in Year 9
10 years
HLOSF
HLOSF
● Live price
90.91%
Share price
$2.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.67M
Annual income
$842,999.04
Full HLOSF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — HLOSF vs GBDC

📍 GBDC pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLOSFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLOSF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLOSF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLOSF
Annual income on $10K today (after 15% tax)
$7,727.27/yr
After 10yr DRIP, annual income (after tax)
$716,549.18/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,214,324.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLOSF + GBDC for your $10,000?

HLOSF: 50%GBDC: 50%
100% GBDC50/50100% HLOSF
Portfolio after 10yr
$11.72M
Annual income
$8,616,131.22/yr
Blended yield
73.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

HLOSF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLOSF buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLOSFGBDC
Forward yield90.91%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$2.67M$20.78M
Annual income after 10y$842,999.04$16,389,263.41
Total dividends collected$2.36M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: HLOSF vs GBDC ($10,000, DRIP)

YearHLOSF PortfolioHLOSF Income/yrGBDC PortfolioGBDC Income/yrGap
1$19,791$9,090.91$12,490$1,790.28+$7.3KHLOSF
2$37,991$16,814.71$16,522$3,157.73+$21.5KHLOSF
3$70,817$30,166.17$23,578$5,898.68+$47.2KHLOSF
4$128,326$52,552.16$37,115$11,886.75+$91.2KHLOSF
5$226,308$88,999.24$66,136$26,423.57+$160.2KHLOSF
6$388,835$146,685.82$137,257$66,491.44+$251.6KHLOSF
7$651,597$235,543.05$341,734$194,868.54+$309.9KHLOSF
8$1,066,101$368,892.48$1,050,788$685,133.02+$15.3KHLOSF
9← crossover$1,704,801$564,073.19$4,099,314$2,974,971.01$2.39MGBDC
10$2,667,136$842,999.04$20,775,530$16,389,263.41$18.11MGBDC

HLOSF vs GBDC: Complete Analysis 2026

HLOSFStock

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

Full HLOSF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HLOSF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLOSF vs SCHDHLOSF vs JEPIHLOSF vs OHLOSF vs KOHLOSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.